The objective of our study was to report real-world data on the safety and efficacy of standard-of-care teclistamab in patients with relapsed/refractory multiple myeloma (MM). This is a multi-institutional retrospective cohort study and included all consecutive patients that received at least one dose of teclistamab up until August 2023. One hundred and ten patients were included, of whom, 86% had triple-class refractory disease, 76% penta-refractory disease, and 35% had prior exposure to B-cell maturation antigen (BCMA)-targeting therapies. The overall response rate (ORR) in our cohort was 62%, with a ≥ very good partial remission (VGPR) rate of 51%. The ORR in patients with and without prior BCMA-targeted therapies was 54% vs 67%, respectively (p = 0.23). At a median follow-up of 3.5 months (range, 0.39–10.92), the estimated 3 month and 6 month progression free survival (PFS) was 57% (95% CI, 48%, 68%) and 52% (95% CI, 42%, 64%) respectively. The incidence of cytokine release syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS) was 56% and 11% respectively, with grade ≥3 CRS and ICANS noted in 3.5% and 4.6% of patients respectively. 78 unique infections were diagnosed in 44 patients, with the incidence of all-grade and grade ≥3 infections being 40% vs 26% respectively. Primary prophylaxis with intravenous immunoglobulin (IVIG) was associated with a significantly lower infection risk on multivariate analysis (Hazard ratio [HR] 0.33; 95% CI 0.17, 0.64; p = 0.001).

我们研究的目的是报告标准护理 teclistamab 对复发/难治性多发性骨髓瘤 (MM) 患者的安全性和有效性的真实世界数据。这是一项多机构回顾性队列研究，纳入了截至 2023 年 8 月接受至少一剂 teclistamab 的所有连续患者。共纳入 110 名患者，其中 86% 患有三级难治性疾病，76% 患有五级难治性疾病- 难治性疾病，35% 之前曾接受过 B 细胞成熟抗原 (BCMA) 靶向治疗。我们队列中的总体缓解率 (ORR) 为 62%，≥非常好的部分缓解 (VGPR) 率为 51%。既往接受过 BCMA 靶向治疗和未接受过 BCMA 靶向治疗的患者的 ORR 分别为 54% 和 67% ( p  = 0.23)。中位随访时间为 3.5 个月（范围为 0.39-10.92），预计 3 个月和 6 个月无进展生存期 (PFS) 分别为 57%（95% CI，48%、68%）和 52%（95% CI 分别为 42%、64%。细胞因子释放综合征（CRS）和免疫效应细胞相关神经毒性综合征（ICANS）的发生率分别为56%和11%，其中≥3级CRS和ICANS的发生率分别为3.5%和4.6%。44名患者中诊断出78种独特感染，全级和≥3级感染的发生率分别为40%和26%。多变量分析显示，静脉注射免疫球蛋白 (IVIG) 一级预防与显着降低的感染风险相关（风险比 [HR] 0.33；95% CI 0.17, 0.64 ；p  = 0.001）。